MDM2 and CDK4 immunohistochemistry results in all tumour groups
| Groups/diagnoses (T) | MDM2 | CDK4 | MDM2 and CDK4 |
| N/T (%) | N/T (%) | N/T (%) | |
| WDLPS (19) | 19/19 (100) | 13/19 (68.4) | 13/19 (68.4) |
| DDLPS (10) | 9/10 (90) | 7/10 (70) | 7/10 (70) |
| WDLPS/DDLPS (29) | 28/29 (96.5) | 20/29 (68.9) | 20/29 (68.9) |
| Other mesenquimal tumours (83) | 29/83 (34.9) | 3/83 (3.6) | 2/83 (2.4) |
| HG-UPS* (26) | 10/26 (38.4) | 1/26 (3.8) | 0/26 (0) |
| MXFBS* (5) | 4/5 (80) | 1/5 (20) | 1/5 (20) |
| FBS* (3) | 1/3 (33.3) | 0/3 (0) | 0/3 (0) |
| LMS* (8) | 2/8 (25) | 0/8 (0) | 0/8 (0) |
| RBMS* (2) | 0/2 (0) | 0/2 (0) | 0/2 (0) |
| MPNST* (7) | 3/7 (42.8) | 0/7 (0) | 0/7 (0) |
| SS (8) | 2/8 (25) | 0/8 (0) | 0/8 (0) |
| EPITS (3) | 1/3 (33.3) | 0/3 (0) | 0/3 (0) |
| KS (2) | 0/2 (0) | 0/2 (0) | 0/2 (0) |
| GIST (4) | 2/4 (50) | 0/4 (0) | 0/4 (0) |
| OTS* (3) | 0/3 (0) | 0/3 (0) | 0/3 (0) |
| DFSP (1) | 1/1 (100) | 0/1 (0) | 0/1 (0) |
| MRLPS* (4) | 1/4 (25) | 0/4 (0) | 0/4 (0) |
| CCS (1) | 0/1 (0) | 0/1 (0) | 0/1 (0) |
| PLPS* (2) | 1/2 (50) | 1/2 (50) | 1/2 (50) |
| LGFMS (1) | 1/1 (100) | 0/1 (0) | 0/1 (0) |
| AGS* (1) | 0/1 (0) | 0/1 (0) | 0/1 (0) |
| EPITH (1) | 0/1 (0) | 0/1 (0) | 0/1 (0) |
| SFT (1) | 0/1 (0) | 0/1 (0) | 0/1 (0) |
| Benign adipocytic tumours (17) | 7/17 (41.1) | 2/17 (11.7) | 1/17 (5.8) |
| NC-LP (6) | 2/6 (33.3) | 0/6 (0) | 0/6 (0) |
| CF-LP (3) | 2/3 (66.6) | 1/3 (33.3) | 1/3 (33.3) |
| PL-LP (2) | 0/2 (0) | 1/2 (50) | 0/2 (0) |
| HIB (1) | 0/1 (0) | 0/1 (0) | 0/1 (0) |
| FBLP (1) | 1/1 (100) | 0/1 (0) | 0/1 (0) |
| IM-LP (1) | 1/1 (100) | 0/1 (0) | 0/1 (0) |
| AMLP (1) | 1/1 (100) | 0/1 (0) | 0/1 (0) |
| NFBLP (1) | 0/1 (0) | 0/1 (0) | 0/1 (0) |
| TLP (1) | 0/1 (0) | 0/1 (0) | 0/1 (0) |
*Neoplasia can simulate DDLPS.
T, total number of cases; N, number of cases; WDLPS, well differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma; PL-LP, pleomorphic lipoma; TLP, timolipoma; SC-LP, spindle cell lipoma; NC-LP, non-conventional lipoma; FBLP, fibrolipoma; NFBLP, neural fibrolipoma; AMLP, angiomyolipoma; HIB, hibernoma; IM-LP, intramuscular lipoma; FBS, fibrosarcoma; GIST, gastrointestinal stromal tumour; MPNST, malignant peripheral nerve sheath tumour; MXFBS, myxofibrosarcoma; HG-UPS, high grade undifferentiated pleomorphic sarcoma; MRLPS, myxoid round cell liposarcoma; LMS, leiomyosarcoma; SS, synovial sarcoma; PLPS, pleomorphic liposarcoma; OTS, osteosarcoma; DFSP, dermatofibrosarcoma protuberans; AGS, angiosarcoma; SFT, solitary fibrous tumours; LGFMS, low grade fibromyxoid sarcoma; EPITS, epithelioid sarcoma; RBMS, rhabdomyosarcoma; EPITH, epithelioid hemangioendothelioma; KS, Kaposi sarcoma; CCS, clear cell sarcoma.